REGENXBIO (NASDAQ:RGNX) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of REGENXBIO (NASDAQ:RGNX – Free Report) from a sell rating to a hold rating in a research report report published on Monday morning.

Several other research firms also recently weighed in on RGNX. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research note on Thursday, November 20th. HC Wainwright reiterated a “buy” rating and set a $34.00 target price on shares of REGENXBIO in a research report on Tuesday, October 7th. Barclays lowered their price target on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of REGENXBIO in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada boosted their target price on shares of REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.63.

Read Our Latest Research Report on REGENXBIO

REGENXBIO Stock Down 1.4%

Shares of RGNX stock opened at $13.26 on Monday. The firm has a market cap of $671.22 million, a P/E ratio of -3.82 and a beta of 1.23. The company has a 50 day moving average of $11.38 and a 200-day moving average of $9.76. REGENXBIO has a 12-month low of $5.03 and a 12-month high of $13.93.

REGENXBIO (NASDAQ:RGNX – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.18. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%.The business had revenue of $29.73 million during the quarter, compared to analyst estimates of $24.41 million. As a group, equities analysts expect that REGENXBIO will post -4.84 EPS for the current year.

Insider Buying and Selling

In other news, CEO Curran Simpson sold 20,811 shares of the business’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $12.62, for a total transaction of $262,634.82. Following the completion of the transaction, the chief executive officer directly owned 216,162 shares in the company, valued at $2,727,964.44. The trade was a 8.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 36,169 shares of company stock valued at $416,598. 12.79% of the stock is owned by company insiders.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in RGNX. Jones Financial Companies Lllp grew its position in REGENXBIO by 44.4% during the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after buying an additional 1,270 shares in the last quarter. Profund Advisors LLC boosted its position in shares of REGENXBIO by 11.8% during the 3rd quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock valued at $139,000 after acquiring an additional 1,523 shares during the last quarter. Pale Fire Capital SE boosted its position in shares of REGENXBIO by 7.7% during the 2nd quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 2,000 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of REGENXBIO by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 2,326 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in shares of REGENXBIO in the third quarter worth approximately $25,000. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

See Also